Introduction
Epilepsy affects up to 2% of the worldwide population, making it one of the most common neurological disorders. 1 Despite the availability of numerous antiepileptic drugs (AEDs) and the continuing emergence of novel AEDs, 30% of patients with epilepsy still suffer from uncontrolled seizures and many experience unpleasant adverse effects. 2 Refractory epilepsy is defined by the International League Against Epilepsy (ILAE) as failure of adequate trials of two tolerated and appropriately chosen and used AED schedules, whether as monotherapies or in combination, to achieve sustained seizure freedom. 3 Currently, some available therapeutic options to help control refractory epilepsy include adjunctive sodium-channel blockers (carbamazepine, lamotrigine, phenytoin, oxcarbazepine), gamma-aminobutyric acid (GABA) inhibitory transmission potentiators (valproic acid, topiramate, clobazam, vigabatrin, phenobarbital), calcium channel modulators/inhibitors (gabapentin, pregabalin, zonisamide, ethosuximide) and synaptic vesicle protein 2A stimulators (levetiracetam), depending on the epilepsy syndrome and seizure type. 4 Similarly, refractory status epilepticus (RSE) is defined as failure of first and second-line agents to terminate the seizure, requiring the addition of a third agent. 5 Many of the same therapeutic options, especially those available in intravenous form, are being investigated in the treatment of RSE. 6 Lacosamide is a new AED believed to exert its anticonvulsant effects through two novel mechanisms of action. The first is through its enhancement of slow inactivation of voltage gated sodium channels (VGSC). Depolarization of VGSCs allows sodium ion influx across neuronal cell membranes, an important step in the initiation of the action potential. After depolarization, VGSCs enter an inactivated state before reverting back to their resting state (where they are available for depolarization again). During the inactivated state, VGSCs are unavailable for depolarization. This fast, inactivated state is milliseconds long and is the site of action of the traditional sodium-channel blockers. In conditions of sustained depolarization and repetitive firing such as epilepsy, VGSCs can undergo a conformational change into the slow inactivation state, which is seconds long. Lacosamide enhances this transition of VGSCs into the slow inactivated state, reducing the availability of VGSCs for depolarization and subsequent neuronal firing. 7 The second potential mechanism of action is lacosamide's binding to collapsin response mediator protein 2 (CRMP-2), which is involved in neuronal differentiation, polarization, and axonal outgrowth. 1 To date, the exact effects of the interaction of lacosamide and CRMP-2 on seizure control have not been determined, and one study suggests lacosamide does not, in fact, bind to CRMP-2. 8 Lacosamide is available as intravenous (IV) and oral formulations. Lacosamide has 100% bioavailability after oral administration and exhibits linear (dose-proportional) pharmacokinetics. Lacosamide's volume of distribution is approximately 0.6 L/kg and binding to plasma proteins is <15%. Lacosamide is metabolized by CYP2C19, CYP2C9, and CYP3A4 into the pharmacologically inactive O-desmethyl-lasosamide. Ninety-five percent of the lacosamide dose is excreted in urine; of this, 40% as unchanged drug, 30% as Odesmethyl-lacosamide, and the remainder as small amounts of additional metabolites. Lacosamide has an elimination half-life of approximately 13 h and appears to have no appreciable pharmacokinetic drug interactions. 9 Advantages of lacosamide as an AED include its availability as both oral and IV formulations, excellent bioavailability, minimal drug interactions, and novel mechanisms of action.
Lacosamide has been available in Europe and the USA since 2008 and in Canada since 2010. 9 The purpose of this paper is to systematically review the available evidence for the efficacy and safety of lacosamide in adult patients with refractory epilepsy and RSE.
Methods
A search of MEDLINE (1948-October 2014), PubMed (1946-October 2014), EMBASE (1980-October 2014), IPA (1970-October 2014), Google and Google Scholar was conducted for articles describing the efficacy and safety of lacosamide in adult patients with refractory epilepsy or RSE. The following search terms were used: lacosamide or harkoseride or Vimpat and epilepsy or seizure or status epilepticus. Reference lists of all identified articles were manually searched. Studies were included if patients were >16 years of age and treated with lacosamide for refractory epilepsy or RSE.
The recent definition of refractory epilepsy (provided by the ILAE) and that of RSE suggest patients should have failed at least two AEDs. In order to ensure all applicable studies were adequately captured, on initial review we included studies that defined refractory epilepsy conservatively as failure to respond to one or more AEDs, provided the population median of failed AEDs prior to lacosamide introduction was 3 or greater. Studies with the following characteristics were excluded: non-human data, not published in English, and published as single case reports or abstract only.
Each study was ranked on the basis of quality of evidence it provided according to the US Preventive Services Task Force 1996 classification system. 10 Level I studies are randomized controlled trials. Level II-1 articles are controlled studies, with patients acting as their own controls or with a parallel control group included. Level II-2 articles are defined as cohort or case-control studies. Level II-3 articles are multiple time series or exceptional descriptive studies. Level III studies are defined as descriptive studies and case reports. 10 Information extracted included study design, number of participants, characteristics of the study population, including previously tried antiepileptic drugs when available, lacosamide dosing regimens, outcome measures, adverse events and any information available on therapeutic drug monitoring.
Results
For refractory epilepsy, the search produced 20 studies, 14 of which were included in this review. Three studies were classified as level I evidence and the remaining 11 were classified as level III evidence. Of the 6 excluded studies, one study was conducted solely in critically ill patients and was included in the RSE review, one study included patients only with brain tumor-related epilepsy, one study did not look at any efficacy outcomes, and 3 studies were single case reports. Results of each study included are described below and summarized in Table 1. 11-24 For RSE, the search produced 22 studies, 13 of which were included in this review. No level I evidence was available. Two studies were level II-2 and the remaining 11 were classified as level III evidence. All 9 excluded studies were single case reports. Results of each study included are described below and summarized in Table 2. 25-37
3.1. Efficacy of lacosamide in refractory epilepsy 3.1.1. Level I evidence Three randomized controlled trials (RCTs) have been conducted assessing the efficacy and safety of lacosamide as adjunctive treatment in adults with refractory epilepsy. All three trials include patients with only focal seizures. [11] [12] [13] In the first RCT by Ben-Menachem et al., 11 patients were randomized to receive oral lacosamide 200 mg/day (100 mg BID), 400 mg/day (200 mg BID), 600 mg/day (300 mg BID) (see Table 1 for titration protocol) or placebo. Patients were eligible if they had focal seizures for at least 2 years despite previous therapy with at least 2 other AEDs and had at least 4 seizures per month (with no seizure-free period longer than 21 days) during an 8-week baseline phase. If patients experienced adverse events during the titration phase, dose reduction was allowed once before the patient was discontinued from the trial. Patients then entered a 12-week maintenance phase.
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Of the 421 patients randomized, 6 were not included in the efficacy analysis due to protocol non-compliance and no postbaseline efficacy assessments.
The intention-to-treat (ITT) populations for lacosamide 400 mg/day and 600 mg/day demonstrated statistically significant median percent reductions in seizure frequency (compared to the placebo group) and proportion of patients with at least 50% and 75% reductions in seizure frequency (Table 1) . Seven patients experienced seizure freedom for the entire 12-week maintenance period (1 in 200 mg/day, 5 in 400 mg/day, and 1 in 600 mg/day groups). Median change in percentage of seizure-free days (i.e., 12%) was statistically significant in both 400 mg/day and 600 mg/ day groups. (4) Headache (3) Slowness of mental reaction (1) Diarrhea (1) Language disturbance (2) Erectile dysfunction (1) Hyponatremia (1) Hypothyroidism (1) Weight gain (2) Disorientation (1) Nausea (1) Parasomnia (1) Rhinitis (1 LTG (35) LEV (25) BDZ (20) TPM (18) ZNM (16) VPA (14) OXC ( Patients in the lacosamide 400 mg/day group experienced the most improvement in quality of life with a Quality of Life in Epilepsy (QOLIE-31) score improvement of 2.7 points compared to an overall score of À1.3 points in the placebo group. A greater proportion of patients showed improvement with the Clinical Global Impression of Change (CGIC) score in the 200 mg/day (35%), 400 mg/day (40%), and 600 mg/day (38%) groups compared to placebo (25%).

Dose proportionality was seen for plasma concentrations of lacosamide and none of the concomitant AED plasma concentrations were affected by lacosamide.
The second RCT, by Halasz et al., 12 randomized patients to receive lacosamide 200 mg/day (100 mg po BID), 400 mg/day (200 mg po BID) or placebo. Inclusion criteria and study protocol were identical to those of Ben-Menachem et al. 11 with the only difference being a 4-week, rather than 6-week titration phase.
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Of the 485 patients randomized, 477 were included in the ITT analysis; 8 patients did not have any post-baseline efficacy assessment. Statistically significant median percent reductions in seizure frequency over placebo were seen in both 200 mg/day and 400 mg/day groups whereas proportion of patients with at least 50% seizure frequency reduction was significantly higher only in the 400 mg/day group (Table 1) . Eleven patients were seizure free throughout the 12-week maintenance phase (5 in 200 mg/day, 3 in 400 mg/day, and 3 in placebo groups). Patients receiving 400 mg/day had significantly more seizure-free days (5%) over placebo. 12 No change in plasma concentrations of any of the other AEDs were found when administered concomitantly with lacosamide. 12 In the most recent RCT, by Chung et al., 13 patients were randomized to receive lacosamide 400 mg/day (200 mg po BID), 600 mg/day (300 mg po BID) or placebo. 13 Inclusion criteria and study protocol were identical to those of Ben-Menachem et al.
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( Table 1) . Of the 405 randomized patients who received at least one dose of lacosamide, 402 had at least one post-baseline efficacy assessment and were included in the ITT analysis. 13 Significant differences were found for both 400 mg/day and 600 mg/day groups compared with placebo in median percent reductions in seizure frequency per month from baseline and proportion of patients with at least 50% and 75% reductions in seizure frequency (Table 1) . 13 There was evidence for dose-related seizure reduction in patients who experienced secondary generalized seizures (n = 176). In placebo (n = 45), lacosamide 400 mg/day (n = 84), and 600 mg/day (n = 47) groups, 50% responder rate was 33.3%, 56% and 70%, respectively. The median percent seizure reduction was 14.3%, 59.4% and 93% in the placebo, lacosamide 400 mg/day, and 600 mg/day groups, respectively. Dose-related seizure reduction was seen in patients with complex partial seizures (n = 331), but not in those with simple partial seizures (n = 149). For the latter patients, those receiving placebo experienced the greatest median percent seizure reduction and had the greatest proportion of patients with at least 50% reduction in seizure frequency. 13 Nine patients were seizure-free throughout the 12-week maintenance period (4 in 400 mg/day and 5 in 600 mg/day groups). Both groups had greater proportion of seizure-free days compared to placebo; (5.3%, p = 0.013) for 400 mg/day and (8.2%, p < 0.001) for 600 mg/day. 13 Dose proportionality was seen with lacosamide plasma concentrations. Plasma concentrations of other AEDs were not affected by lacosamide except for one patient who had low valproic acid (VPA) levels in the 600 mg/day lacosamide group. Lacosamide was unlikely to be the cause of this as no other patients who were receiving VPA experienced this effect. [14] [15] [16] [17] [18] [19] [20] Only one study included patients with both focal and generalized seizures. 18 In the first study, by Wehner et al., 14 25 patients with refractory focal epilepsy were followed for 6 months after initiation of oral lacosamide as adjunctive treatment. In addition to the other concomitant AEDs, 3 patients had prior epilepsy surgery, 6 had undergone vagus nerve stimulator placement, 2 were scheduled to undergo respective epilepsy surgery and 2 had been offered the surgery but declined. Twenty patients (80%) were taking lacosamide in addition to another sodium-channel blocker AED.
14 During the 6-month follow up, 3 patients had periods of seizure freedom lasting 1, 4, and 5 months. Of the 8 patients with at least 50% reduction in seizure frequency (Table 1) , 6 were on another sodium-channel blocker AED in addition to lacosamide. One patient receiving pregabalin and lamotrigine substituted the lamotrigine with lacosamide and experienced a 100% increase in seizure frequency. 14 In a study by Garcia-Morales et al., 15 60 patients treated with oral adjunctive lacosamide for refractory focal seizures were assessed for efficacy and safety for 13-24 months. Overall, a 50% response rate was seen in 28 patients (47%), with 11/17 patients (65%) in the nocturnal seizure group and 17/43 patients (40%) in the daytime seizure group (Table 1) . Difference between these two groups was not statistically different, although the study was not powered to show this. 15 In patients taking lacosamide with other sodium-channel blockers, the 50% response rate was seen in 18/40 (45%) vs. 15/20 (75%) in patients taking lacosamide in combination with non-sodium-channel blocking AEDs. 15 In a prospective descriptive audit by Stephen et al., 16 113
patients with refractory focal epilepsy received oral lacosamide 200-400 mg/day. Doses were titrated until one of the following endpoints: seizure freedom for !6 months, at least 50% reduction in seizure frequency (responder), <50% reduction in seizure frequency for !6 months on highest tolerated lacosamide dose (marginal responder) or lacosamide withdrawal because of side effects, lack of efficacy or both. Sixty-five patients reached an endpoint, but no other data were provided for the remaining 48 (Table 1) . 16 Patients were more likely to stay seizure free when lacosamide was the first add-on AED (15/36, 41.7%) compared to later in the treatment schedule (1/27, 3.7%, p = 0.001). Seizure freedom was just as likely to occur in patients taking other sodium-channel blockers (5/26, 19.2%) as those taking other AEDs with different mechanisms of action (11/37, 29.7%). Complete seizure freedom was achieved in one patient on lacosamide monotherapy at a dose of 200 mg/day after VPA had been withdrawn due to signs of neurotoxicity. Overall, of the 65 patients whose data were available, 78% had benefit with the addition of lacosamide 16 (see also Table 1) .
A prospective descriptive study, by Husain et al., 17 is an openlabel extension of the RCT by Chung et al. 13 Patients from that RCT were asked if they would like to participate in the extension and, if they agreed, were placed on oral lacosamide 200 mg/day at the conclusion of the RCT. During this study, lacosamide dosages could be decreased to 100 mg/day or increased up to 800 mg/day maximum. Concomitant AEDs could also be dose-adjusted or added or discontinued. The duration of follow up ranged from 3 to 5 years. 17 Nine patients (8 who experienced a median percent reduction in monthly seizure frequency ranging from 53.6% to 100%) were maintained on lacosamide monotherapy for >6 months and 8 patients (7 who sustained at least 50% reductions in seizure frequency over the entire treatment period) for >12 months. 17 (see also By the end of the 12-month follow-up period, 2 (3.4%) patients remained seizure-free, 23 (39%) remained responders (at least a 50% seizure frequency reduction), and 10 (16.9%) remained nonresponders. No statistically significant differences between groups by seizure type were found. An increase in seizure frequency was seen in 3 (5%) patients at 3 months, 2 (3.4%) at 6 months and no patients experienced an increase in seizure frequency at 12 months follow up. 18 In a prospective, multicenter descriptive study by Villanueva et al., 19 158 patients with focal seizures were started on lacosamide therapy and followed for 12 months. All patients had tried at least one AED prior to this study; however, 5 patients were not receiving any therapy at enrollment.
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At 12 months, nearly a quarter of patients were seizure-free and nearly half were responders, defined as at least a 50% reduction in seizure frequency (Table 1) . Three-and 6-month seizure free rates were 22.8% and 15.8%, respectively; 3-and 6-month responder rates were 44.3% and 46.2%, respectively. There were fewer seizure-free patients who were already on a sodium-channel blocker compared to those on concomitant AEDs with different mechanisms of action (34.7% vs. 17.3%, p = 0.017) as well as fewer responders (65.3% vs. 37.5%, p = 0.001). However, neither seizurefree nor responder rates differed among different epilepsy types or etiologies (data not presented). 19 Novy et al., 20 in the most recent prospective observational study, evaluated efficacy and safety of lacosamide treatment in 376 adult patients with refractory epilepsy who were treated for a median duration of 1.6 years. Thirty-seven percent of patients had some period of seizure improvement or seizure freedom ( [21] [22] [23] [24] Three studies included patients with both focal and generalized seizure types. [21] [22] [23] In the first retrospective descriptive study, by Flores et al., 21 403 patients with focal or generalized epilepsy treated with lacosamide and had at least one follow-up clinic visit were retrospectively reviewed for efficacy and safety of lacosamide, with all outcomes compared to a 3-month baseline.
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Of 403 patients reviewed, 347 achieved the minimum 3 months follow up and were included in the analysis. At 3 months, 108 patients (31.1%) had at least 50% reduction in seizure frequency, 98 (28.2%) had <50% reduction in seizure frequency, 50 (14.4%) had increase in seizures, and 91 (26.2%) were unchanged. 21 In the last 3 months of follow up, 285 patients were included in the analysis. Of these patients, 102 (35.7%) had at least 50% reduction in seizure frequency, 62 (21.7%) had seizure frequency reduction of <50%, 53 (18.6%) had increase in seizure frequency and 68 patients (23.8%) were unchanged. 21 Of 3 seizure subtypes (generalized tonic-clonic, complex partial, and simple partial), highest seizure reduction and seizure-free rates were seen in patients with tonic-clonic seizures. 21 In a subgroup analysis at one of the study centers, outcomes in 116 patients who were involved in final follow-up analysis were compared between patients taking lacosamide plus another sodium-channel blocking agent vs. other AEDs with different mechanisms of action. Most patients (92.2%) had focal seizures. There was no difference between the two groups regarding 50% reduction in seizure frequency or being seizure-free. 21 In the second retrospective study, Harden et al. 22 reviewed 67 patients with refractory epilepsy treated with lacosamide. Fortysix of 67 patients (69%) achieved the primary efficacy outcome of at least 50% reduction in seizure frequency. Mean daily dose of these responders was 293 mg compared to 243 mg in patients who did not respond. Twenty-two patients, including two patients receiving lacosamide monotherapy, had no seizures in the most recent treatment month. Fifty-three patients took concurrent sodiumchannel blocking AEDs; 34 were responders (64%) vs. 12 of the 14 patients (86%) not taking concurrent sodium-channel blocking AEDs (p > 0.05). 22 Kamel et al., 23 conducted a retrospective review of 128 patients who received lacosamide for treatment of focal or generalized seizures (Table 1) . Average time patients were seizure free on lacosamide was 35 weeks. Forty-four patients (34%) had no response; no patients had seizure worsening. There was no significant difference in reduction of seizure frequency between the higher lacosamide doses (>200 mg/day) compared to lower lacosamide doses (<200 mg/day). Nor was there significant difference in the subgroup of patients taking concurrent sodium-channel blocking agents in terms of 50% responders. However, this study was not powered to a detect difference in either outcome. 23 In the most recent, and largest, retrospective descriptive study, by Villanueva et al., 24 efficacy and safety of lacosamide was investigated over a one-year period in 500 patients with focal epilepsy and classified into early add-on treatment group (previously failed 1 or 2 AEDs prior to starting lacosamide: 20.4%) and late add-on treatment group (previously failed at least 3 AEDs prior to starting lacosamide: 79.6%). 24 At least 50% reduction in seizure frequency occurred in 74.7% of the early add-on group compared to 52.6% of the late add-on group (p < 0.001). Seizure freedom occurred in 41.4% of the early vs. 8.1% of the late add-on groups (p < 0.001) ( Table 1) . 24 Patients not taking concomitant sodium-channel blockers had higher seizure-free rates compared to those receiving concomitant sodium-channel blocking AEDs at all evaluation timepoints, 3 months (22.8% vs. 13.5%; p = 0.014), 6 months (24.1% vs. 12.3%; p = 0.001) and 12 months (27.1% vs. 12.3%; p < 0.001). No specific combinations of adjunctive lacosamide with other AEDs were found to be associated with responder or seizure-free rates. December 2011 in a single center, who had not previously received IV lacosamide were identified. The standardized protocol is presented in Table 2 . In 2009, IV lacosamide became available and was used as one of the non-sedating third-line agents; or, at the neurologist's discretion, lacosamide could have been used as the second agent. 25 Of 111 patients with RSE, 29 had focal motor or absence SE, 10 had generalized convulsive SE (GCSE), and 72 had non-convulsive SE (NCSE). Twenty-five patients with SE caused by hypoxicischemic encephalopathy were excluded due to overall poor outcomes associated with this seizure type, leaving 86 patients in the comparative cohort. Forty-five of these patients were treated with IV lacosamide. Lacosamide was the final AED administered to 51% of patients. Seven percent received lacosamide concurrently with a second-line AED. While duration of SE and seizure control numerically favored lacosamide treatment, these did not reach statistical significance. Mortality significantly improved with lacosamide therapy when adjusted for age (OR 0.34, 95% CI 0.1-0.9), but no significant differences were seen in discharge destination. 25 In a retrospective cohort study by Kellinghaus et al., 26 all adult patients diagnosed with RSE from August 2008 to December 2010 in a single center, were identified. Forty-six patients with varying seizure types who had failed first-line benzodiazepine and a second-line AED (levetiracetam in 85% of patients) were included. Patients given phenytoin (median 1500 mg IV) or lacosamide (median 400 mg IV) as third-line agent (36/46, 78%) were analyzed.
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Of the 36 patients compared, 15 patients received phenytoin and 21 lacosamide, with mean time from seizure onset to administration of third agent of 14.5 and 19 h, respectively. No significant differences were found between the groups in overall seizure termination rates or time to seizure termination (see Table 2 ). 27 34 patients diagnosed with RSE (28 focal motor SE, 5 NCSE and one GCSE) who had received IV lacosamide following use of a standard protocol (see Table 2 ) were identified prospectively from 6 Spanish hospitals. 27 Efficacy, defined as cessation of seizures with no change in AED for at least 48 h after clinical or electrographic seizure resolution, was achieved in 64.7% of patients, the majority of SE ceasing within 12 h of the first lacosamide dose (Table 2) . Further AED or anesthetic therapy was required in 12 patients. 27 In the second prospective case series by Legros et al., 28 25 patients diagnosed with RSE (n = 21) or seizure cluster (n = 4) who had received IV lacosamide following failure of at least 3 other AEDs either acutely or chronically were identified prospectively from a Belgian medical need program. 28 Lacosamide 200 mg IV bolus was initially used from October 2010 to June 2011, and due to poor initial results, lacosamide 400 mg IV bolus was subsequently used per protocol from July 2011 to December 2012. Response, defined as lacosamide being the last AED added before seizure termination, was achieved in 36% of patients, with no statistically significant difference in response between the two dosages. Early seizure termination within 3 h of lacosamide administration was significantly greater in the 400 mg dose group (Table 2) . 28 3.2.2.2. Retrospective non-comparative case series. Nine retrospective case series have assessed efficacy and safety of lacosamide in adults with RSE. [29] [30] [31] [32] [33] [34] [35] [36] [37] The case series, consisting of 4-55 patients, encompassed a range of seizure types including refractory focal, non-convulsive, and generalized convulsive SE. In all cases, benzodiazepine and multiple AEDs were used in an attempt to terminate seizure activity, with lacosamide added in as first-to fifth-line or greater (median, third-line or greater). Loading doses ranged from 50 to 400 mg IV and were followed by 50-400 mg/day IV maintenance dosages. Efficacy, defined as seizure cessation after administration of lacosamide, was 0-100%.
The largest retrospective study, Garces et al., reviewed 55 patients with RSE within a total population of 98 that included 43 patients with acute repetitive seizures or seizure clusters. 37 Only results of RSE patients are presented. The majority of patients received lacosamide as the third (or more) AED. Thirty-nine of 55 patients (70.9%) achieved the primary efficacy outcome of seizure cessation after lacosamide administration. In multivariate analysis, no single factor [i.e., order of lacosamide administration (first-/ second-line vs. third-line or later), time to administration, concurrent sodium-channel blocker, seizure type, and lacosamide dose ( 200 mg vs. >200 mg)] significantly influence response; however, bivariate analysis indicated shorter time to lacosamide administration and NCSE seizure type were associated with significantly greater chance of response. 37 Kellinghaus et al. 32 reviewed 39 patients with focal or generalized RSE treated with an IV lacosamide bolus, with the majority of patients receiving it as the third or greater AED. Seventeen of 39 patients (44%) achieved the primary efficacy outcome of seizure cessation after lacosamide administration.
Rates of efficacy were higher in those who received lacosamide earlier in the sequence, with approximately 60% of patients responding when lacosamide was given as third-line treatment or earlier, and 20% when given as fourth-line or greater.
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Hö fler et al. 31 reviewed 31 patients with refractory focal, NCSE, or convulsive SE given IV lacosamide. One patient received lacosamide as first-line agent, with all others failing benzodiazepines or other AEDs, and lacosamide given as the third or fourth agent. Seizures were terminated in 81% of patients, with similar efficacy regardless of when lacosamide was given in relation to other AEDs. 31 The remaining 6 retrospective case series each included 4-10 patients. 29, 30, [33] [34] [35] [36] Lowest efficacy rates were seen by Goodwin et al., 30 where 0 of 9 patients responded to IV lacosamide within a 4-h timeframe from administration or remained seizure free for 24 h following emergence from burst suppression sedation. Using low-dose lacosamide bolus of 50-100 mg IV demonstrated an efficacy rate of seizure termination of 100% in 4 patients with refractory NCSE within 2 h, 33 to 20% in 10 episodes of primarily non-convulsive RSE. 34 
Safety and tolerability of lacosamide in adult patients
Side effects and discontinuation rates for each study are listed in Tables 1 and 2 . Total number of patients who received lacosamide in this review was 3899, although frequency of adverse events was not reported in every study.
The more commonly reported adverse events included dizziness (826/3899, 21.2%), diplopia/blurred vision (394, 10.1%), drowsiness/ sedation/somnolence (283, 7.3%), headache (265, 6.8%), nausea (247, 6.3%), ataxia/balance/coordination problems (221, 5.7%), vomiting (139, 3.6%), fatigue (120, 3.1%), tremor (83, 2.1%), nystagmus (80, 2.1%), upper respiratory tract infection (URTI) (71, 1.8%), nasopharyngitis (71, 1.8%), contusion (58, 1.5%), falls (49, 1.3%), depression (48, 1.2%), skin laceration (39, 1.0%), and back pain (34, 0.9%).
Eighty-eight patients (2.3%) experienced worsening of seizures on lacosamide (Flores et 14, 15, 18, 20, 21, 28 indicating that lacosamide may not be suitable for every patient. Unfortunately, at this time, we cannot predict which patients will experience this outcome.
A few studies reported on rate of adverse events in patients taking lacosamide with other concurrent sodium-channel blocking AEDs compared to those taking lacosamide with AEDs with different mechanisms of action. 21 reported no difference in adverse events or withdrawals between patients on concurrent sodium-channel blockers and those not.
Other rare, but sometimes serious, adverse events were observed in some trials. In Ben-Mehachem et al., 11 electrocardiograms (ECGs) revealed no prolongation of QT interval, but a small increase in PR interval (4.2 ms for the 400 mg/day dose) and firstdegree AV block occurred in 3 patients (no lacosamide discontinuation for these adverse events). In Halasz et al., 12 2 patients in the 400 mg/day lacosamide group experienced a psychotic disorder. ECGs showed no QT prolongation but a small increase in PR interval of 4.6 ms in patients on 400 mg/day. In Chung et al., 13 ECG showed no effect on QT interval but a small increase in PR interval of 4.4 ms and 6.1 ms for patients in the 400 mg/day and 600 mg/ day lacosamide treatment groups, respectively. In Garces et al., 37 2 patients, both with underlying ischemic cardiomyopathy, demonstrated ECG changes. One had asymptomatic PR interval prolongation after a 200 mg infusion, with resolution upon dose reduction. The other had third-degree AV block after 400 mg IV (total) was administered with concurrent beta blocker. Lacosamide was withdrawn in this patient until a permanent pacemaker was implanted. In Wehner et al., 14 2 patients both on lacosamide 400 mg/day lost >10% of their body weight. In Husain et al. 17 serious adverse events considered related to trial medication included atrial fibrillation and ventricular extra systoles (2 patients). There were also two reports of suicidal ideation (no other information was given). In the RSE case series by Goodwin et al., 30 two of 9 patients had acute angioedema thought to be related to IV administration of lacosamide; one required discontinuation of lacosamide. Discontinuation rates in the refractory epilepsy trials ranged from 12.4% 16 to 55.2% 17 The most common reason for discontinuation in 7 studies was adverse events. 11, 15, 16, 19, 21, 22, 24 Discontinuation was rare in the RSE trials.
Discussion
To the best of our knowledge, this systematic review is the first to evaluate clinical efficacy and safety of lacosamide for refractory seizures (including focal and generalized epilepsy) and refractory status epilepticus in adults, using all published evidence (including post-marketing data).
Currently, lacosamide is approved for use in adult patients for adjunctive treatment of refractory focal seizures. In the US only, lacosamide is also approved for monotherapy in adult patients with focal seizures. 9 In the 3 RCTs, [11] [12] [13] lacosamide demonstrated efficacy over placebo for median percent seizure reduction ranging from 26% to 40% at doses of 200 mg/day, 13 400 mg/day [11] [12] [13] and 600 mg/day, 11, 12 and for proportion of patients with at least 50% reduction in seizure frequency ranging from 33% to 41% of patients at doses of 400 mg/day [11] [12] [13] and 600 mg/day. 11, 12 While RCTs sit atop the hierarchy of evidence and are important for establishing efficacy and safety, these phase II/III trials do not always accurately reflect efficacy and tolerability of new medications in the routine clinical setting due to their short durations and strict exclusion criteria. Altogether, 11 postmarketing descriptive studies in refractory epilepsy [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] revealed a response rate of at least 50% reduction in seizure frequency in 18-69% of patients. Although not every study reported seizure freedom, this important outcome was achieved in 3-33% of patients. 11, 16, [19] [20] [21] [22] [23] None of the post-marketing observational studies explicitly evaluate or discuss the issue of tolerance; however, five of these studies 17, 24 did evaluate efficacy at different time points during the follow-up period. Husain et al., 17 had the longest follow-up period of five years. There was no decline in median percent reduction in seizure frequency or proportion of 50% responders over the followup period; however, this was evaluated based on patients remaining in the study. Novy et al., 20 had the second longest follow-up period of up to three years with 51 (14%) patients retaining 50% seizure frequency reduction at end of follow up. Verotti et al., 18 and both studies by Villanueva et al., 19, 24 had follow-up periods of 12 months with efficacy evaluations occurring at three, six and 12 months. While Verotti et al., 18 showed a mild decrease in 50% responders over the 12-month period, one study by Villanueva et al., 19 showed no difference in response rate and the other study by Villanueva et al., 24 saw an increase in the proportion of patients with a 50% decrease in seizure frequency over the 12 months. While tolerance does not seem to occur with lacosamide use, more studies with longer follow-up periods evaluating this are required. Currently, lacosamide is not approved for treatment of generalized epilepsy. 9 While Harden et al., 22 Lacosamide is not currently approved for use in SE and no RCTs are available in this population. Animal models suggested that early treatment with lacosamide significantly and dose-dependently reduced SE seizure activity. 25 These initial findings, in addition to the availability of an IV formulation, the apparent lack of significant cardiac or respiratory effects associated with IV infusion, and minimal drug interactions make lacosamide an attractive agent for ongoing study in SE. Of the available studies in this population, one comparative cohort study documented no significant improvement in duration of SE or seizure control with addition of lacosamide in RSE patients, 26 and another showed no difference in efficacy compared with phenytoin for seizure termination and time to seizure termination. 27 Eleven postmarketing descriptive studies using lacosamide as add-on therapy in RSE revealed seizure termination rates of 0-100% (median 64.7%). [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] These studies included varied seizure types of SE (focal, generalized-convulsive, non-convulsive and myoclonic). Due to the small numbers of patients, varying seizure types and wide range of effectiveness reported, the role of IV lacosamide for RSE treatment remains unknown. The small numbers of adverse events reported in these RSE trials, however, may make it an attractive option in these patients who fail standard therapy. All of the refractory epilepsy studies evaluated lacosamide as adjunctive therapy; however, a few studies included some patients on lacosamide monotherapy. Husain et al. 17 included 8 patients receiving lacosamide monotherapy for at least 12 months and 7 of them sustained at least 50% reductions in seizure frequency over the entire treatment period. Although Villanueva et al., 19 Kamel et al., 23 Harden et al. 22 and Novy et al. 20 had small numbers of patients receiving lacosamide monotherapy (n = 13), these studies did not specifically report patient outcomes. A larger historical controlled trial published by Wechsler et al. evaluating the use of lacosamide monotherapy in patients with focal seizures showed efficacy of lacosamide monotherapy at doses of 400 mg per day. 39 Lacosamide is now approved for monotherapy use in adults with focal epilepsy but still remains only approved for use as adjunctive treatment in Canada and Europe. Several refractory epilepsy studies also evaluated efficacy of lacosamide, a novel sodium-channel blocker, in combination with other sodium-channel blockers compared to lacosamide in combination with AEDs with different mechanisms of action. While Garcia-Morales et al. 15 showed that more patients receiving lacosamide in combination with AEDs with different mechanisms of action had at least 50% reduction in seizure frequency compared to lacosamide in combination with other sodium-channel blockers, 3 other studies [21] [22] [23] showed no difference between the two groups.
Villanueva et al. 24 found a higher seizure-free rate in patients receiving AEDs of different mechanisms of action in addition to lacosamide compared to the other sodium-channel blockers while Stephen et al. 16 found seizure freedom just as likely in either group.
Unfortunately, at this time, there is insufficient and conflicting information to be able to recommend specific AED combinations with lacosamide. The most commonly reported adverse events of lacosamide in adults were dizziness, vision disturbances, headache, nausea, balance and coordination problems, drowsiness, sedation, somnolence, vomiting, fatigue, tremor, nystagmus, URTI, nasopharyngitis, contusion, falls, depression, skin laceration, and back pain. Adverse events were similar between all 14 refractory epilepsy studies, with dizziness being predominant and a primary reason for lacosamide discontinuation. Few adverse events were reported with IV lacosamide for RSE, and three patients of 264 studied required discontinuation of lacosamide.
A few published case reports describe possible lacosamideassociated cardiac events such as sinus node dysfunction, atrial fibrillation/flutter and ventricular tachycardia. [40] [41] [42] In the 3 RCTs 11-13 and one extension study, 17 monitoring for possible cardiac adverse events was conducted and PR interval prolongations were noted in all 4 studies. Although there were no serious clinical implications and none of the other observational studies noted any cardiac-related adverse events, pharmacovigilance and reporting of cardiac abnormalities is still required as more patients use this new agent. As in analysis of efficacy, several studies also investigated whether there were differences in adverse events between patients taking lacosamide with other sodium-channel blockers compared to patients on concomitant AEDs with different mechanisms of action. Of the 8 studies 14, 15, [19] [20] [21] [22] [23] [24] were phase II/III clinical trials for approval of lacosamide, had strict exclusion criteria, and were conducted for short periods (12 weeks) . This has implications in terms of occurrence of adverse events given that some adverse events take time to manifest and may be less likely to occur in healthier patients. Also, in all 3 RCTs, [11] [12] [13] there was a titration phase and patients were discontinued from the trial if they required a second-dose alteration due to adverse events. This procedure removes patients from the trial who were most likely to experience adverse events of lacosamide. Of note, for all trials included in this review, the majority of adverse events were patient-or caregiver-reported. This introduces recall bias and possibly inaccurate reporting. The retrospective nature of some studies adds the element of possible underreporting and erroneous recording of adverse events in the medical record.
All of the non-comparative studies share some similar limitations in that they were observational by design with no comparator and had small sample sizes. Hence, some studies were not designed to detect improved clinical outcomes compared to clinical practice prior to the availability of lacosamide. Also, although the number of patients included in each study was based on those who received at least one dose of lacosamide, many patients were omitted from efficacy and safety analysis due to lack of tolerability during the titration periods or lack of adequate follow up. Removing such patients may skew results, potentially making lacosamide seem less efficacious than it may be, or seem better tolerated than it may be.
Most of the included studies relied on patient and caregiver reports of seizure frequency by means of a seizure diary. Not only does this introduce recall bias but also seizures must be clinically noticeable in order to be recorded, and depending on the type of seizure, this may not always be the case.
Despite the aforementioned limitations, all studies included in this review, with the exception of a single RSE study, 30 showed varying degrees of benefit, with minimal adverse effects, when adding lacosamide to therapy of focal refractory seizures and RSE in adult patients. In patients with difficult-to-treat epilepsy experiencing multiple seizures per day, reduction in seizure frequency will most likely improve their quality of life, although this outcome was only specifically tested by Ben-Menachem et al., 11 in which patients receiving 400 mg/day lacosamide scored better on the QOLIE 31 scale compared to placebo. That, coupled with other advantages including no known clinically relevant drug interactions and availability of an IV formulation, make lacosamide an attractive option in these setting.
Conclusion
This systematic review of the literature assessing use of lacosamide in adult patients revealed 14 studies including a total of 3509 patients with refractory epilepsy and 13 studies including a total of 390 patients with RSE. Based on this evidence, lacosamide, used in combination with other AEDs, was well tolerated and reduced seizure frequency by at least 50% in 18-69% of patients with refractory focal seizures, and was effective in terminating seizures in patients with RSE. Dosing for treatment of refractory epilepsy appears to be patient-specific but can be initiated at 100 mg/day divided twice daily and titrated over a period of 4-6 weeks to maximal doses of 600-800 mg/day divided twice daily. An adequate trial of lacosamide appears to be 12 weeks. Loading doses of 50-400 mg IV can be used to treat RSE. Ongoing pharmacovigilance is required for monitoring of adverse events.
